Search results
Added:
1 year ago
ESC-HFA 2023 — Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352).
The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from ESC Heart Failure 2023 revealed that dapagliflozin…
View more
Start date:
May 13, 2024
End date:
May 13, 2024
Radcliffe Medical Education is hosting a symposium entitled 'A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure' at theHeart Failure Association (HFA)in Lisbon, PT, on Monday 13th May 2024 at 12:30 - 13:30 UTC+1.Add to your calendar.OverviewThis symposium will focus on the importance of accurate and rapid diagnosis for patients empowering physicians to promptly initiate…
View more
Added:
10 months ago
Added:
2 months ago
Added:
1 year ago
ACC.24 — We are joined onsite by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF DM Trial (NCT04916470).The STEP HFpEF DM study aimed to investigate the effect of taking semaglutide 2.4mg once weekly in patients with heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus type 2. The study looked at the impact of…
View more
Added:
6 months ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the…
View more
Added:
1 year ago
Added:
1 year ago
ESC-HFA 2023 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the PARAGLIDE-HF trial (NCT03988634).
The PARAGLIDE-HF aimed to evaluate the effects of sacubitril/valsartan compared to valsartan on changes in NT-proBNP, safety and tolerability in HFpEF patients who have…
View more
Added:
1 year ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935).
ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were…
View more
Added:
1 year ago
